SARS-CoV-2 spike-protein targeted serology test results and their association with subsequent COVID-19-related outcomes.

ABSTRACT:

Importance

In the absence of evidence of clinical utility, the United States' Centers for Disease Control and Prevention does not currently recommend the assessment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike-protein antibody levels. Clinicians and their patients, especially immunocompromised patients, may benefit from an adjunctive objective clinical laboratory measure of risk, using SARS-CoV-2 serology.

Objective

The aim of this study is to estimate the association between SARS-CoV-2 spike-protein targeted antibody levels and clinically relevant outcomes overall and among clinically relevant subgroups, such as vaccine and immunocompetency statuses.

Design

A retrospective cohort study was conducted using laboratory-based data containing SARS

SUBMITTER: Kaufman HW 

PROVIDER: S-EPMC10407563 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature